Purpuric Drug Eruption Secondary to Fidaxomicin

Mucci, Tania; Davis-Lorton, Mark

doi:10.1097/ipc.0b013e318281d8d7

Cited by 2 publications

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The largest review of fidaxomicin-associated hypersensitivity reactions was published in 2013 by the FDA, which summarized reports submitted to FAERS (n = 11 cases) and 1 report described in the literature since market approval in 2011. 13,14 To our knowledge, the FDA review and the aforementioned pre-existing case report are the only published cases at the time of writing our report. Of the 12 reactions, 4 involved diffuse rash, including 1 report of purpuric cutaneous reaction.…”

Section: Discussionmentioning

confidence: 98%

Fidaxomicin-Associated Hypersensitivity Reactions: Report of a Morbilliform Drug Eruption

Molleti

Bidell

Tatara

2022

Journal of Pharmacy Practice

View full text Add to dashboard Cite

Purpose We report a probable case of morbilliform drug eruption secondary to fidaxomicin in a patient with Clostridioides difficile infection (CDI). Summary A 62-year-old female presented to our institution’s emergency department (ED) with symptoms consistent with Clostridioides difficile infection. The patient was prescribed 2 weeks of oral vancomycin for CDI prior to presentation. Given insufficient response to vancomycin, the patient was started on fidaxomicin with a planned 10-day course. After 2 doses of fidaxomicin, the patient developed a rash on her back that spread within 24 hours. The patient did not experience relief upon administration of a variety of medications for allergic reaction. Improvement was noted upon discontinuation of fidaxomicin. The Food and Drug Administration reports that < 2% of adults treated with fidaxomicin experience a rash as an adverse effect. Conclusion Fidaxomicin was a probable cause of morbilliform drug eruption in our patient with CDI. The patient improved upon discontinuation of fidaxomicin.

show abstract

Section: Discussionmentioning

confidence: 98%